Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT2i, Hepatic Glucose Production, and SNS
Sponsor: The University of Texas Health Science Center at San Antonio
Summary
In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. Principal Investigator (PI) will conduct five distinct experiments to test this hypothesis in patients with T2D. To examine the role of the SNS on the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D by comparing the effect of empagliflozin versus empagliflozin plus propranolol.
Official title: Protocol II: SGLT2i, Hepatic Glucose Production, and Sympathetic Nervous System (SNS)
Key Details
Gender
All
Age Range
30 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
22
Start Date
2025-01-07
Completion Date
2027-06-30
Last Updated
2025-07-11
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 25 MG
A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
Locations (1)
Texas Diabetes Institute/UH
San Antonio, Texas, United States